Alto Neuroscience (ANRO) Interest Coverage Ratio (2023 - 2026)
Alto Neuroscience (ANRO) posted Interest Coverage Ratio of 49.79 for Q1 2026, down 170.07% sequentially from 71.06 in Q4 2025, and down 535.3% YoY from 11.44 in Q1 2025.
Powered by 
Analysis
Alto Neuroscience (ANRO) Interest Coverage Ratio (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Interest Coverage Ratio for 4 years, with the latest figure at 49.79 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 535.3% year-over-year to 49.79 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 119.18 (down 241.01% YoY) and the FY2025 annual result came in at 1.27, up 30.62% from the prior year.
- Interest Coverage Ratio slipped to 49.79 in Q1 2026 per ANRO's latest filing, from 71.06 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 16997.0 in Q4 2024 and troughed at 54.11 in Q3 2024.
- A 4-year average of 1301.14 and a median of 22.23 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2026: Interest Coverage Ratio surged 14636.03% in 2024, then tumbled 535.3% in 2026.
- Over 4 years, Interest Coverage Ratio stood at 115.34 in 2023, then soared by 14636.03% to 16997.0 in 2024, then slumped by 99.58% to 71.06 in 2025, then plunged by 170.07% to 49.79 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 49.79, 71.06, and 0.01 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | -59.33 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -59.33 |
| Mar 31, 2026 | -49.79 |
| Dec 31, 2025 | -29.66 |
| Sep 30, 2025 | -23.00 |
| Jun 30, 2025 | -28.92 |
| Mar 31, 2025 | -26.21 |
| Dec 31, 2024 | -51.04 |
| Sep 30, 2024 | -54.11 |
| Jun 30, 2024 | -52.86 |
| Mar 31, 2024 | -41.58 |
| Dec 31, 2023 | -33.05 |
| Sep 30, 2023 | -26.77 |
| Jun 30, 2023 | -27.91 |
| Mar 31, 2023 | -22.23 |